Active Biotech AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-37.32	-39.4	-45.8	-58.37	-49.83	Upgrade
Depreciation & Amortization	1.6	1.64	1.68	1.5	1.28	Upgrade
Stock-Based Compensation	-	0.01	0.17	0.69	0.28	Upgrade
Other Operating Activities	-	-	-	-	-0	Upgrade
Change in Accounts Receivable	1.11	-1.09	-0.17	0.03	0.99	Upgrade
Change in Other Net Operating Assets	2.22	-1.58	-1.62	1.31	1.1	Upgrade
Operating Cash Flow	-32.4	-40.42	-45.74	-54.85	-46.17	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-0.25	-	Upgrade
Investing Cash Flow	-	-	-	-0.25	-	Upgrade
Long-Term Debt Repaid	-1.71	-1.64	-1.62	-1.76	-1.02	Upgrade
Net Debt Issued (Repaid)	-1.71	-1.64	-1.62	-1.76	-1.02	Upgrade
Issuance of Common Stock	78.53	35.19	43.47	46.83	76.25	Upgrade
Other Financing Activities	-6.72	-1.96	-1.68	-1.31	-2.15	Upgrade
Financing Cash Flow	70.1	31.59	40.16	43.76	73.09	Upgrade
Net Cash Flow	37.7	-8.82	-5.58	-11.34	26.92	Upgrade
Cash Interest Paid	-	0	0	-	0	Upgrade
Levered Free Cash Flow	-7.03	-34.26	-29.14	-32.65	-27.12	Upgrade
Unlevered Free Cash Flow	-6.96	-34.15	-28.99	-32.53	-27.1	Upgrade
Change in Working Capital	3.33	-2.67	-1.79	1.34	2.1	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.